Idarubicin Hexal

Idarubicin, the active ingredient in Idarubicin Hexal, is an anthracycline antibiotic presented as a sterile injectable solution for intravenous use. It is employed in the treatment of acute myeloid leukemia in adult patients, targeting rapidly dividing malignant cells to achieve remission.

GNH USA supplies Idarubicin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing quality‑assured products that meet European Union regulatory standards. The company ensures timely delivery, proper cold‑chain handling, and comprehensive documentation for import compliance.

Idarubicin is an anthracycline used in the management of acute myeloid leukemia and related disease states.

Acute Myeloid Leukemia (de novo): induces remission in newly diagnosed patients Relapsed Acute Myeloid Leukemia: provides a therapeutic option after prior treatment failure High‑Risk Acute Myeloid Leukemia: used as part of consolidation therapy to reduce relapse risk

Idarubicin may cause a range of adverse reactions, varying from frequent to rare but serious.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported - Alopecia: hair loss due to effects on rapidly dividing cells - Myelosuppression: decreased blood cell counts leading to anemia, neutropenia, or thrombocytopenia - Mucositis: inflammation of the mouth and gastrointestinal lining

Serious or Rare Side Effects: - Cardiotoxicity: irreversible heart muscle damage that may lead to heart failure - Severe neutropenic infection: life‑threatening bacterial or fungal infections due to profound neutropenia - Secondary malignancies: increased risk of developing new cancers after treatment

When using Idarubicin, several precautions should be observed to minimize risks and ensure safe administration. - Cardiac monitoring: baseline and periodic echocardiograms are recommended due to risk of cardiotoxicity. - Hematologic assessment: complete blood counts should be performed regularly to detect myelosuppression. - Liver function evaluation: hepatic impairment may alter drug clearance, requiring dose consideration. - Avoid concurrent anthracyclines: cumulative exposure increases risk of cardiac and marrow toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicin interacts with several agents; awareness of these interactions helps prevent enhanced toxicity or reduced efficacy.

Major Interactions (Avoid): - Other anthracyclines: additive cardiotoxicity and marrow suppression. - Cyclophosphamide: synergistic myelosuppression may be severe. - Radiation therapy: combined treatment can increase tissue damage and fibrosis.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): CYP3A4 inhibition may raise Idarubicin plasma levels. - Warfarin: altered anticoagulant effect requiring INR monitoring. - Loop diuretics (e.g., furosemide): may exacerbate electrolyte disturbances and affect cardiac function.